LENZ Therapeutics
LENZ
55 hedge funds and large institutions have $362M invested in LENZ Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 20 closing their positions.
344% more capital invested
Capital invested by funds: $81.5M → $362M (+$281M)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
187.43% more ownership
Funds ownership: 7.65% → 195.08% (+187%)
13% less funds holding
Funds holding: 63 → 55 (-8)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
42% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 24
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$86.9M |
| 2 |
AWG
Alpha Wave Global
New York
|
+$75.1M |
| 3 |
7IH
72 Investment Holdings
Stamford,
Connecticut
|
+$21.2M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$20.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$2.66M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.15M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.54M |
| 4 |
Renaissance Technologies
New York
|
-$752K |
| 5 |
Two Sigma Advisers
New York
|
-$354K |
LENZ Hedge Fund Activity: Q1 2024 in Review
55 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q1 2024, worth a combined $362M — up 344% from $81.5M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LENZ and 12 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 14 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $86.9M. The largest seller was Prosight Management, cutting an estimated $2.66M.
- 55 institutional investors held LENZ Therapeutics (LENZ) as of Q1 2024, down from 63 in Q4 2023.
- Funds reported $362M of LENZ Therapeutics stock for Q1 2024, up 344% quarter-over-quarter.
- 12 funds opened new LENZ Therapeutics positions in Q1 2024 and 20 closed out, a net change of -8 holders.
- The largest LENZ Therapeutics buyer in Q1 2024 was RA Capital Management, an estimated $86.9M added.
- The largest LENZ Therapeutics seller in Q1 2024 was Prosight Management, an estimated $2.66M sold.
Based on aggregated 13F filings for Q1 2024.